Interest in kidney diseases is mounting among investors, biotechs and pharmas at a rate reminiscent of the liver disease explosion almost a decade ago. The momentum is driven by improvements at both ends of the...

Marketed treatments for polycystic kidney disease manage symptoms but do not slow disease progression. A research team led by Genzyme Corp. now has shown that blocking biosynthesis of the glycosphingolipid glucosylceramide could help treat the...